Determination of liver specific toxicities in rat hepatocytes by high content imaging during 2-week multiple treatment

Toxicology in Vitro

Volumn 30, Issue 1, 2015, Pages 79-94

  Germano, Davide ^a   Uteng, Marianne ^a   Pognan, Francois ^a   Chibout, Salah Dine ^a   Wolf, Armin ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Hepatotoxicity; High content imaging; In vitro model; Long term culture; Rat hepatocytes; Safety profiling

Indexed keywords

AMIODARONE; CHLORPROMAZINE; COLLAGEN TYPE 1; CYCLOSPORIN A; FENOFIBRATE; IBUPROFEN; LIPID; METFORMIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; PARACETAMOL; PHOSPHOLIPID; ROSIGLITAZONE; TROGLITAZONE; VALPROIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CHROMAN DERIVATIVE; CYCLOSPORIN; DOPAMINE RECEPTOR BLOCKING AGENT; IMMUNOSUPPRESSIVE AGENT; POTASSIUM CHANNEL BLOCKING AGENT;

ANIMAL CELL; ARTICLE; CELL CULTURE; CHRONIC DRUG ADMINISTRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CYTOTOXICITY; DRUG SAFETY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEPATOBILIARY SYSTEM; HIGH CONTENT IMAGING; IMAGING; IN VITRO STUDY; IN VIVO STUDY; LIPID STORAGE; LIPIDOSIS; LIVER CELL; LIVER FUNCTION; MALE; NONHUMAN; PROTEIN TRANSPORT; RAT; STEATOSIS; TOXIC HEPATITIS; ANIMAL; CELL CULTURE TECHNIQUE; DRUG EFFECTS; GENE EXPRESSION REGULATION; WISTAR RAT;

AMIODARONE; ANIMALS; CELLS, CULTURED; CHLORPROMAZINE; CHROMANS; CULTURE TECHNIQUES; CYCLOSPORINE; DOPAMINE ANTAGONISTS; GENE EXPRESSION REGULATION; HEPATOCYTES; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; MALE; POTASSIUM CHANNEL BLOCKERS; RATS; RATS, WISTAR; THIAZOLIDINEDIONES;

EID: 84902938188     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2014.05.009     Document Type: Article

References (99)

1. Ballantyne C.M., Podet E.J., Patsch W.P., Harati Y., Appel V., Gotto A.M., Young J.B. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989, 262:53-56.
2. Barth A., Bergmann R., Zaumseil J., Klinger W. Influence of drugs on bile acid excretion. Arch. Toxicol. Suppl. 1978, 359-361.
3. Begriche K., Massart J., Robin M.A., Borgne-Sanchez A., Fromenty B. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J. Hepatol. 2011, 54:773-794.
4. Berridge B.R., Chatman L.A., Odin M., Schultze A.E., Losco P.E., Meehan J.T., Peters T., Vonderfecht S.L. Phospholipidosis in nonclinical toxicity studies. Toxicol. Pathol. 2007, 35:325.
5. Blaauboer B.J. Biokinetic modeling and in vitro-in vivo extrapolations. J. Toxicol. Environ. Health, Part B 2010, 13:242-252.
6. Blotnik S., Bergman F., Bialer M. Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats. Drug Metab. Dispos. 1996, 24:560-564.
7. Bohme M., Buchler M., Muller M., Keppler D. Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett. 1993, 333:193-196.
8. Bolesta S., Haber S.L. Hepatotoxicity associated with chronic acetaminophen administration in patients without risk factors. Ann. Pharmacother. 2002, 36:331-333.
9. Borst P., Zelcer N., van de Wetering K. MRP2 and 3 in health and disease. Cancer Lett. 2006, 234:51-61.
10. Broeders J.J., Blaauboer B.J., Hermens J.L. In vitro biokinetics of chlorpromazine and the influence of different dose metrics on effect concentrations for cytotoxicity in Balb/c 3T3, Caco-2 and HepaRG cell cultures. Toxicol. In Vitro 2013, 27:1057-1064.
11. Carey D.G., Cowin G.J., Galloway G.J., Jones N.P., Richards J.C., Biswas N., Doddrell D.M. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. Obes. Res. 2002, 10:1008-1015.
12. Choi Y.H., Lee U., Lee B.K., Lee M.G. Pharmacokinetic interaction between itraconazole and metformin in rats: competitive inhibition of metabolism of each drug by each other via hepatic and intestinal CYP3A1/2. Br. J. Pharmacol. 2010, 161:815-829.
13. Coecke S., Pelkonen O., Leite S.B., Bernauer U., Bessems J.G., Bois F.Y., Gundert-Remy U., Loizou G., Testai E., Zaldivar J.M. Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches. Toxicol. In Vitro 2013, 27:1570-1577.
14. Donato M.T., Tolosa L., Jimenez N., Castell J.V., Gomez-Lechon M.J. High-content imaging technology for the evaluation of drug-induced steatosis using a multiparametric cell-based assay. J. Biomol. Screen. 2012, 17:394-400.
15. Dunn J.C., Tompkins R.G., Yarmush M.L. Long-term in vitro function of adult hepatocytes in a collagen sandwich configuration. Biotechnol. Prog. 1991, 7:237-245.
16. Ertorer M.E., Paydas S., Sagliker Y. Hyperbilirubinemia in a renal transplant patient due to cyclosporin A therapy. Nephron 1997, 76:368.
17. Farkas D., Tannenbaum S.R. Characterization of chemically induced hepatotoxicity in collagen sandwiches of rat hepatocytes. Toxicol. Sci. 2005, 85:927-934.
18. Feinstein D.L., Spagnolo A., Akar C., Weinberg G., Murphy P., Gavrilyuk V., Dello R.C. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?. Biochem. Pharmacol. 2005, 70:177-188.
19. Finsterer J., Zarrouk M.S. Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders. Expert. Opin. Drug Metab Toxicol. 2012, 8:71-79.
20. Floyd J.S., Barbehenn E., Lurie P., Wolfe S.M. Case series of liver failure associated with rosiglitazone and pioglitazone. Pharmacoepidemiol. Drug Saf 2009, 18:1238-1243.
21. Foster J.R., Jacobsen M., Kenna G., Schulz-Utermoehl T., Morikawa Y., Salmu J., Wilson I.D. Differential effect of troglitazone on the human bile acid transporters, MRP2 and BSEP, in the PXB hepatic chimeric mouse. Toxicol. Pathol. 2012, 40:1106-1116.
22. Fromenty B., Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol. Ther. 1995, 67:101-154.
23. Fruncillo R.J., Bernhard R., Swanson B.N., Vlasses P.H., Ferguson R.K. Effect of phenobarbitone on the pharmacokinetics and tissue levels of amiodarone in the rat. J. Pharm. Pharmacol. 1985, 37:729-731.
24. Fujimura H., Dekura E., Kurabe M., Shimazu N., Koitabashi M., Toriumi W. Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development. Exp. Toxicol. Pathol. 2007, 58:375-382.
25. Fujimura H., Murakami N., Kurabe M., Toriumi W. In vitro assay for drug-induced hepatosteatosis using rat primary hepatocytes, a fluorescent lipid analog and gene expression analysis. J. Appl. Toxicol. 2009, 29:356-363.
26. Funk C., Ponelle C., Scheuermann G., Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol. 2001, 59:627-635.
27. Gardner C.R., Heck D.E., Yang C.S., Thomas P.E., Zhang X.J., DeGeorge G.L., Laskin J.D., Laskin D.L. Role of nitric oxide in acetaminophen-induced hepatotoxicity in the rat. Hepatology 1998, 27:748-754.
28. Gerk P.M., Vore M. Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J. Pharmacol. Exp. Ther. 2002, 302:407-415.
29. Guan P., Lu Y., Qi J., Niu M., Lian R., Hu F., Wu W. Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. Int. J. Nanomedicine 2011, 6:965-974.
30. Guguen-Guillouzo C., Guillouzo A. General review on in vitro hepatocyte models and their applications. Methods Mol. Biol. 2010, 640:1-40.
31. Halliwell W.H. Cationic amphiphilic drug-induced phospholipidosis. Toxicol. Pathol. 1997, 25:53-60.
32. Hirode M., Ono A., Miyagishima T., Nagao T., Ohno Y., Urushidani T. Gene expression profiling in rat liver treated with compounds inducing phospholipidosis. Toxicol. Appl. Pharmacol. 2008, 229:290-299.
33. Hruban Z. Pulmonary and generalized lysosomal storage induced by amphiphilic drugs. Environ. Health Perspect. 1984, 55:53-76.
34. Imamura Y., Harada S., Okano Y., Miyata T., Otagiri M. The effect of metoclopramide on the absorption and pharmacology of chlorpromazine in the rat. J. Pharm. Pharmacol. 1988, 40:116-119.
35. Ishizaki J., Ito S., Jin M., Shimada T., Ishigaki T., Harasawa Y., Yokogawa K., Takami A., Nakao S., Miyamoto K. Mechanism of decrease of oral bioavailability of cyclosporin A during immunotherapy upon coadministration of amphotericin B. Biopharm. Drug Dispos. 2008, 29:195-203.
36. Kahan B.D. Cyclosporine. N. Engl. J. Med. 1989, 321:1725-1738.
37. Kartenbeck J., Leuschner U., Mayer R., Keppler D. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 1996, 23:1061-1066.
38. Khan M.S., Akhter M. Synthesis, pharmacological activity and hydrolytic behavior of glyceride prodrugs of ibuprofen. Eur. J. Med. Chem. 2005, 40:371-376.
39. Kim Y., Lasher C.D., Milford L.M., Murali T.M., Rajagopalan P. A comparative study of genome-wide transcriptional profiles of primary hepatocytes in collagen sandwich and monolayer cultures. Tissue Eng. Part C Methods 2010, 16:1449-1460.
40. Kobayashi M., Saitoh H., Kobayashi M., Tadano K., Takahashi Y., Hirano T. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J. Pharmacol. Exp. Ther. 2004, 309:1029-1035.
41. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 2004, 3:711-715.
42. Kuroda Y., Saito M. Prediction of phospholipidosis-inducing potential of drugs by in vitro biochemical and physicochemical assays followed by multivariate analysis. Toxicol. In Vitro 2010, 24:661-668.
43. Labbe G., Pessayre D., Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam. Clin. Pharmacol. 2008, 22:335-353.
44. Lakshmi K.S., Rajesh T. Rosiglitazone quantification in rat plasma using high performance liquid chromatography with mass spectrometric detection and its application to pre-clinical pharmacokinetic studies. PDA. J. Pharm. Sci. Technol. 2011, 65:100-108.
45. LeCluyse E.L., Audus K.L., Hochman J.H. Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration. Am. J. Physiol. 1994, 266:C1764-C1774.
46. Lal J., Jain G.K. Effect of centchroman coadministration on the pharmacokinetics of metformin in rats. Indian J. Pharmacol. 2010, 42:146-149.
47. Lee M.H., Hong I., Kim M., Lee B.H., Kim J.H., Kang K.S., Kim H.L., Yoon B.I., Chung H., Kong G., et al. Gene expression profiles of murine fatty liver induced by the administration of valproic acid. Toxicol. Appl. Pharmacol. 2007, 220:45-59.
48. Lee M.H., Kim M., Lee B.H., Kim J.H., Kang K.S., Kim H.L., Yoon B.I., Chung H., Kong G., Lee M.O. Subchronic effects of valproic acid on gene expression profiles for lipid metabolism in mouse liver. Toxicol. Appl. Pharmacol. 2008, 226:271-284.
49. Lewis J.H., Mullick F., Ishak K.G., Ranard R.C., Ragsdale B., Perse R.M., Rusnock E.J., Wolke A., Benjamin S.B., Seeff L.B., et al. Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum. Pathol. 1990, 21:59-67.
50. Lewis J.H., Zimmerman H.J., Garrett C.T., Rosenberg E. Valproate-induced hepatic steatogenesis in rats. Hepatology 1982, 2:870-873.
51. Li X., Gu L., Xu Y., Wang Y. Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats. Drug Dev. Ind. Pharm. 2009, 35:827-833.
52. Lloyd S., Hayden M.J., Sakai Y., Fackett A., Silber P.M., Hewitt N.J., Li A.P. Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors. Chem. Biol. Interact. 2002, 142:57-71.
53. Loi C.M., Alvey C.W., Vassos A.B., Randinitis E.J., Sedman A.J., Koup J.R. Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites. J. Clin. Pharmacol. 1999, 39:920-926.
54. Mayerson A.B., Hundal R.S., Dufour S., Lebon V., Befroy D., Cline G.W., Enocksson S., Inzucchi S.E., Shulman G.I., Petersen K.F. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002, 51:797-802.
55. McDonough P.M., Agustin R.M., Ingermanson R.S., Loy P.A., Buehrer B.M., Nicoll J.B., Prigozhina N.L., Mikic I., Price J.H. Quantification of lipid droplets and associated proteins in cellular models of obesity via high-content/high-throughput microscopy and automated image analysis. Assay. Drug Dev. Technol. 2009, 7:440-460.
56. McKim J.M. Building a tiered approach to in vitro predictive toxicity screening: a focus on assays with in vivo relevance. Comb. Chem. High Throughput Screen. 2010, 13:188-206.
57. Menon K.V.N., Angulo P., Lindor K.D. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. Am. J. Gastroenterol. 2001, 96:1631-1634.
58. Morelli J.K., Buehrle M., Pognan F., Barone L.R., Fieles W., Ciaccio P.J. Validation of an in vitro screen for phospholipidosis using a high-content biology platform. Cell Biol. Toxicol. 2006, 22:15-27.
59. Myara A., Cadranel J.F., Dorent R., Lunel F., Bouvier E., Gerhardt M., Bernard B., Ghoussoub J.J., Cabrol A., Gandjbakhch I., et al. Cyclosporin A-mediated cholestasis in patients with chronic hepatitis after heart transplantation. Eur. J. Gastroenterol. Hepatol. 1996, 8:267-271.
60. Newa M., Bhandari K.H., Kim J.A., Yoo B.K., Choi H.G., Yong C.S., Woo J.S., Lyoo W.S. Preparation and evaluation of fast dissolving ibuprofen-polyethylene glycol 6000 solid dispersions. Drug Deliv. 2008, 15:355-364.
61. Obata T. Intrahepatic cholestasis and hyperbilirubinemia in ethynyl estradiol and chlorpromazine-treated rats. Gastroenterol. Jpn. 1983, 18:538-548.
62. Ohshiro S., Hobara N., Sakai M., Hokama N., Kameya H., Sakanashi M. Effects of salicylate on the pharmacokinetics of valproic acid after oral administration of sodium valproate in rats. Biog. Amines 2003, 17:401-407.
63. Oikawa H., Maesawa C., Sato R., Oikawa K., Yamada H., Oriso S., Ono S., Yashima-Abo A., Kotani K., Suzuki K., et al. Liver cirrhosis induced by long-term administration of a daily low dose of amiodarone: a case report. World J. Gastroenterol. 2005, 11:5394-5397.
64. Paine A.J. The maintenance of cytochrome P-450 in rat hepatocyte culture: some applications of liver cell cultures to the study of drug metabolism, toxicity and the induction of the P-450 system. Chem. Biol. Interact. 1990, 74:1-31.
65. Paine A.J., Williams L.J., Legg R.F. Apparent maintenance of cytochrome P 450 by nicotinamide in primary cultures of rat hepatocytes. Life Sci. 1979, 24:2185-2191.
66. Parmentier C., Truisi G.L., Moenks K., Stanzel S., Lukas A., Kopp-Schneider A., Alexandre E., Hewitt P.G., Mueller S.O., Richert L. Transcriptomic hepatotoxicity signature of chlorpromazine after short- and long-term exposure in primary human sandwich cultures. Drug Metab. Dispos. 2013, 41:1835-1842.
67. Paulusma C.C., Bosma P.J., Zaman G.J., Bakker C.T., Otter M., Scheffer G.L., Scheper R.J., Borst P., Oude Elferink R.P. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 1996, 271:1126-1128.
68. Pedersen J.M., Matsson P., Bergstrom C.A., Norinder U., Hoogstraate J., Artursson P. Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J. Med. Chem. 2008, 51:3275-3287.
69. Poucell S., Ireton J., Valencia-Mayoral P., Downar E., Larratt L., Patterson J., Blendis L., Phillips M.J. Amiodarone-associated phospholipidosis and fibrosis of the liver Light, immunohistochemical, and electron microscopic studies. Gastroenterology 1984, 86:926-936.
70. Reasor M.J., Kacew S. Drug-induced phospholipidosis: are there functional consequences?. Exp. Biol. Med. (Maywood) 2001, 226:825-830.
71. Regal R.E., Billi J.E., Glazer H.M. Phenothiazine-induced cholestatic jaundice. Clin. Pharm. 1987, 6:787-794.
72. Rodrigues M., Alves G., Abrantes J., Falcao A. Herb-drug interaction of Fucus vesiculosus extract and amiodarone in rats: A potential risk for reduced bioavailability of amiodarone in clinical practice. Food Chem. Toxicol. 2012, 52C:121-128.
73. Roman I.D., Monte M.J., Gonzalez-Buitrago J.M., Esteller A., Jimenez R. Inhibition of hepatocytary vesicular transport by cyclosporin A in the rat: relationship with cholestasis and hyperbilirubinemia. Hepatology 1990, 12:83-91.
74. +-ATPase activities of canalicular-enriched rat liver plasma membranes. Gastroenterology 1978, 74:1183-1190.
75. Schurdak M.E., Vernetti L.A., Abel S.J., Thiffault C. Adaptation of an in vitro phospholipidosis assay to an automated image analysis system. Toxicol. Mech. Methods 2007, 17:77-86.
76. Seglen P.O. Preparation of isolated rat liver cells. Methods Cell Biol. 1976, 13:29-83.
77. Shaikh N.A., Downar E., Butany J. Amiodarone - an inhibitor of phospholipase activity: a comparative study of the inhibitory effects of amiodarone, chloroquine and chlorpromazine. Mol. Cell Biochem. 1987, 76:163-172.
78. Stone B.G., Udani M., Sanghvi A., Warty V., Plocki K., Bedetti C.D., Van Thiel D.H. Cyclosporin A-induced cholestasis. The mechanism in a rat model. Gastroenterology 1987, 93:344-351.
79. Tang W. Drug metabolite profiling and elucidation of drug-induced hepatotoxicity. Expert Opin. Drug Metab. Toxicol. 2007, 3:407-420.
80. Tanneberger K., Rico-Rico A., Kramer N.I., Busser F.J., Hermens J.L., Schirmer K. Effects of solvents and dosing procedure on chemical toxicity in cell-based in vitro assays. Environ. Sci. Technol. 2010, 44:4775-4781.
81. Terui K., Saito T., Hishiki T., Sato Y., Mitsunaga T., Yoshida H. Hepatic expression of multidrug resistance protein 2 in biliary atresia. Comp. Hepatol. 2011, 10:6.
82. Tolosa L., Pinto S., Donato M.T., Lahoz A., Castell J.V., O'Connor J.E., Gomez-Lechon M.J. Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs. Toxicol. Sci. 2012, 127:187-198.
83. Tong V., Teng X.W., Chang T.K., Abbott F.S. Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Toxicol. Sci. 2005, 86:436-443.
84. Tuschl G., Hrach J., Walter Y., Hewitt P.G., Mueller S.O. Serum-free collagen sandwich cultures of adult rat hepatocytes maintain liver-like properties long term: a valuable model for in vitro toxicity and drug-drug interaction studies. Chem. Biol. Interact. 2009, 181:124-137.
85. van de Water F.M., Havinga J., Ravesloot W.T., Horbach G.J., Schoonen W.G. High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis. Toxicol. In Vitro 2011, 25:1870-1882.
86. Varanasi K.K., Potharaju S., Rajak S., Veeraraghavan S., Mallick P., Vakkalanka S.K. Effect of pentoxifylline on the pharmacokinetics of rosiglitazone in Wistar rats. Methods Find. Exp. Clin. Pharmacol. 2008, 30:537-542.
87. Wiesner R.H., Ludwig J., Lindor K.D., Jorgensen R.A., Baldus W.P., Homburger H.A., Dickson E.R. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N. Engl. J. Med. 1990, 322:1419-1424.
88. Waitzkin L. Prolonged hepatic dysfunction after clinical recovery from chlorpromazine jaundice. Gastroenterology 1962, 43:337-339.
89. Wilke R.A., Lin D.W., Roden D.M., Watkins P.B., Flockhart D., Zineh I., Giacomini K.M., Krauss R.M. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat. Rev. Drug Discov. 2007, 6:904-916.
90. Wolf A., Müller S.-O., Hewitt P., Pfaller W., Jennings P., Testai E., Bois F., Prieto P., Price A., Lukas A., Richet L., Guillouzo A., Leonard M., Blaauboer B., Rostami A., Reinert K., Honegger P., Cechelli R., Kopp-Schneider A., Weiss D., Schröder O., Huber C., Dekant W. Predict-IV project overview (EU grant 202222)-non animal-based toxicity profiling by integrating toxicodynamics and biokinetics. Toxicology Letters 2013, 221S:S7.
91. Xu J.J., Diaz D., O'Brien P.J. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem. Biol. Interact. 2004, 150:115-128.
92. Xu J.J., Henstock P.V., Dunn M.C., Smith A.R., Chabot J.R., de G.D. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 2008, 105:97-105.
93. Yamada T., Arai T., Nagino M., Oda K., Shoda J., Suzuki H., Sugiyama Y., Nimura Y. Impaired expression of hepatic multidrug resistance protein 2 is associated with posthepatectomy hyperbilirubinemia in patients with biliary cancer. Langenbecks Arch. Surg. 2005, 390:421-429.
94. Yamamoto K., Onishi H., Ito A., Machida Y. In vitro and in vivo evaluation of medicinal carbon granules and tablet on the adsorption of acetaminophen. Int. J. Pharm. 2007, 328:105-111.
95. Yamasaki I., Uotsu N., Yamaguchi K., Takayanagi R., Yamada Y. Effects of kale ingestion on pharmacokinetics of acetaminophen in rats. Biomed. Res. 2011, 32:357-362.
96. Zamek-Gliszczynski M.J., Xiong H., Patel N.J., Turncliff R.Z., Pollack G.M., Brouwer K.L. Pharmacokinetics of 5 (and 6)-carboxy-2',7'-dichlorofluorescein and its diacetate promoiety in the liver. J. Pharmacol. Exp. Ther. 2003, 304:801-809.
97. Zhang G., Terry A.V., Bartlett M.G. Simultaneous determination of five antipsychotic drugs in rat plasma by high performance liquid chromatography with ultraviolet detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 856:20-28.
98. Ziegler K., Frimmer M. Cyclosporin A and a diaziridine derivative inhibit the hepatocellular uptake of chocolate, phalloidin and rifampicin. Biochim. Biophys. Acta 1986, 855:136-142.
99. Zimmerman H.J., Ishak K.G. Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology 1982, 2:591-597.